Key Drivers
- Strong Liquidity
- Heavy Cash Burn
- Funding Dependence
AIAI Summary
REPL has shifted from a near-term FDA dead-end to a narrow resubmission/de-risking story, but after the sharp rally the stock now trades ahead of proof while heavy cash burn and dilution risk mean investors should treat it as a catalyst-driven trade rather than a fundamentals-backed compounder.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Heavy Cash Burn
- •Funding Dependence
REPL remains highly liquid and debt-manageable, but zero revenue, persistent operating and free-cash-flow losses, and dependence on financing make it a cash-runway story rather than an earnings story.
Price Behavior
Key Price Behavior Insights:
- •Breakout surge
- •Higher highs
- •Overextended move
REPL has surged strongly over the last month in a breakout-driven uptrend, but the move looks extended and may need a pause unless it holds support near $8.87-$9.00.
Sharp jump from the mid-$4s to the high-$8s after 2026-05-28
Sentiment & News
Key News Insights:
- •FDA reset
- •Legal scrutiny
- •ASCO data
Replimune shifted from securities-law scrutiny and repeated FDA setbacks to a sharp rebound after aligning with the FDA on RP1 resubmission and reporting encouraging ASCO clinical data.
The news flow materially improved sentiment and could support REPL shares if the resubmission path and clinical momentum hold
Similar Companies in Healthcare
Other companies in the same sector with AI ratings